EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENTExclusive Clinical Study and Data License Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT (the “Agreement”) is made as of June 12, 2009 (the “Effective Date”) between VIROPHARMA INCORPORATED, a Delaware corporation (“ViroPharma”), and GENZYME CORPORATION, a Massachusetts corporation (“Genzyme”).
ContractShare Purchase Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations
[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ****, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]
AMENDMENT NO. 2 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATEDExclusive Clinical Study and Data License Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment”) to the Exclusive Clinical Study and Data License Agreement dated June 12, 2009 (the “Agreement”) by and between Genzyme Corporation (“Genzyme”) and ViroPharma Incorporated (“ViroPharma”), as amended on October 21, 2009, is effective as of April 5, 2010 (“Amendment Effective Date”).
DEVELOPMENT AND OPTION AGREEMENT Dated as of December 22, 2011 by and between VIROPHARMA INCORPORATED and MERITAGE PHARMA, INC.Development and Option Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”) is made and entered into as of December 22, 2011 by and between ViroPharma Incorporated, a Delaware corporation (“Optionee”), and Meritage Pharma, Inc., a Delaware corporation (the “Company”).
AMENDMENT NO. 1 TO EXCLUSIVE CLINICAL STUDY AND DATA LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND VIROPHARMA INCORPORATEDExclusive Clinical Study and Data License Agreement • February 28th, 2012 • Viropharma Inc • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) to the Exclusive Clinical Study and Data License Agreement dated June 12, 2009 (the “Agreement”) by and between Genzyme Corporation (“Genzyme”) and ViroPharma Incorporated (“ViroPharma”), is effective as of October 22, 2009 (“Amendment Effective Date”).
